Obinutuzumab (Gazyva) is a B-cell-targeted monoclonal antibody being tested for the treatment of systemic lupus erythematosus (SLE).[3][4] A phase III study called ALLEGORY demonstrated that obinutuzumab in combination with standard of care achieves a statistically significant and clinically meaningful improvement compared to standard of care alone.[3][4] All major secondary study objectives were met, including improvement in disease activity and reduction in the need for corticosteroids.[3] The safety profile of the drug was consistent with previous experience with its use for other indications.[1] Obinutuzumab is already approved in 100 countries for the treatment of various forms of lymphoma and is currently being investigated for the treatment of lupus nephritis (an inflammatory kidney disease caused by lupus).[1] The positive results suggest that obinutuzumab could become a new treatment option for SLE patients on standard therapy.